Author

Yu-Zhuo Wang

h-index 16 View on Semantic Scholar

We have 3 of 58 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Deep learning-based histologic classifiers enable molecular subtyping of metastatic prostate cancer.

Metastatic prostate cancer is a clinically and molecularly heterogeneous disease. Under the selective pressure of androgen receptor (AR)-directed therapies, resistant phenotypes frequently emerge, posing significant diagnostic and therapeutic challenges. Neuroendocrine prostate cancer (NEPC) is a clinically important p...

Zhi-Jun Chen, Erolcan Sayar, D. Guevara et al. · JCI Insight · 0 citations

Open access Aug 2026

Combined BET bromodomain and DNMT inhibition targets critical survival pathways in transdifferentiated prostate cancer.

Lineage plasticity, or transdifferentiation, is increasingly recognized as a resistance mechanism to androgen receptor (AR) inhibition in prostate cancer. Lineage plasticity is characterized by loss of AR signaling and epithelial differentiation, along with activation of stemness-associated pathways, epithelial-mesench...

W. Storck, Diana Flores, A. Kumaraswamy et al. · JCI Insight · 0 citations

Jul 2026

DNMT3B drives neuroendocrine lineage plasticity and aggressive progression in prostate cancer.

It is demonstrated that DNMT3B is required for both the initiation and maintenance of the NEPC phenotype, and its inhibition suppresses NEPC growth and differentiation, highlighting it as a promising therapeutic target for treatment-resistant disease.

Yunsol Jo, H. Jung, Zi-Qin Wang et al. · Molecular Cancer Research · 0 citations